Procollagen type III aminoterminal propeptide as biomarker of host response in severe sepsis

Journal of Critical Care

Volumn 28, Issue 5, 2013, Pages 577-585

  Zakynthinos, Spyros ^a   Papanikolaou, Spyros ^c   Mentzelopoulos, Spyros ^a   Konstandelou, Evangellia ^c   Psachoulia, Christina ^b   Mavrommatis, Antonis ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c GENERAL HOSPITAL OF NIKEA   (Greece)

Author keywords

Biomarkers; Host response; Sepsis; Septic shock; Severe sepsis

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; PROCALCITONIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; INTENSIVE CARE UNIT; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; OBSERVATIONAL STUDY; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; RADIOIMMUNOASSAY; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK;

BIOMARKERS; HOST RESPONSE; SEPSIS; SEPTIC SHOCK; SEVERE SEPSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEPSIS; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC;

EID: 84883560621     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2013.04.004     Document Type: Article

References (40)

1. Levy M.M., Fink M.P., Marshall J.C., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003, 31:1250-1256.
2. Bernard G.R., Vincent J.-L., Laterre P.-F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
3. Vincent J.-L., de Mondonca A., Cantraine F., et al. Use of SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med 1998, 26:1793-1800.
4. Rubulotta F., Marshall J.C., Ramsay G., Nelson D., Levy M., Williams M. Predisposition, insult/infection, response, and organ dysfunction: a new model for staging severe sepsis. Crit Care Med 2009, 37:1329-1335.
5. Harbarth S., Holeckova K., Froidevaux C., et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001, 164:396-402.
6. Brunkhorst F.M., Wegschneider K., Forycki Z.F., Brunkhorst R. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 2000, 26:S148-S152.
7. Gardlund B., Sjolin J., Nilsson A., Roll M., Wickerts C.J., Wretlind B. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis 1995, 172:296-301.
8. Presneill J.J., Waring P.M., Layton J.E., et al. Plasma granulocyte-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: relation to disease severity, multiple organ dysfunction, and mortality. Crit Care Med 2000, 28:2344-2354.
9. Raaphorst J., Groeneveld J., Bossink A.W., Eric Hack C. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost 2001, 86:543-549.
10. Martins G.A., Da Gloria Da Carvalho M., Rocha Gattass C. Sepsis: a follow-up of cytokine production in different phases of septic patients. Int J Mol Med 2003, 11:585-591.
11. Groeneveld J.A.B., Tacx A.N., Bossink J.A.W., van Mierlo J.G., Hack E.C. Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection. Clin Immunol 2003, 106:106-115.
12. Meduri G.U. The role of the host defence response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment. Eur Respir J 1996, 9:2650-2670.
13. Horslev-Petersen K. Circulating extracellular matrix components as markers for connective tissue response to inflammation. Dan Med Bull 1990, 37:308-329.
14. Kivirikko K.J., Myllyla R. Post-translational processing of procollagens. Ann N Y Acad Sci 1985, 460:187-201.
15. Kirk J.E., Bateman E.D., Haslam P., Laurent G.J., Turner-Warwick M. Serum type III procollagen peptide concentration in cryptogenic fibrosing alveolitis and its clinical relevance. Thorax 1984, 39:726-732.
16. Entzian P., Huckstadt A., Kreipe H., Barth J. Determination of serum concentrations of type III procollagen peptide in mechanically ventilated patients: pronounced augmented concentrations in the adult respiratory distress syndrome. Am Rev Respir Dis 1990, 142:1079-1082.
17. Waydhas C., Nast-Kolb D., Trupka A., et al. Increased serum concentrations of procollagen type III peptide in severely injured patients: an indicator of fibrosing activity?. Crit Care Med 1993, 21:240-247.
18. Gaddnas F., Koskela M., Koivukangas V., et al. Markers of collagen synthesis and degradation are increased in serum in severe sepsis: a longitudinal study of 44 patients. Crit Care 2009, 13:R53.
19. Meduri G.U., Tolley E.A., Chinn A., Stentz F., Postlethwaite A. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 1998, 158:1432-1441.
20. 2 removal. Eur J Clin Chem Clin Biochem 1991, 29:805-812.
21. Clark J.G., Milberg J.A., Steinberg K.P., Hudson L.D. Type III procollagen peptide in the adult respiratory distress syndrome: association of increased peptide levels in bronchoalveolar lavage fluid with increased risk for death. Ann Intern Med 1995, 122:17-23.
22. Chesnutt A.N., Matthay M.A., Tibayan F.A., Clark J.G. Early detection of type III procollagen peptide in acute lung injury. Pathogenetic and prognostic significance. Am J Respir Crit Care Med 1997, 156:840-845.
23. Marshall R.P., Bellingan G., Webb S., et al. Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome. Am J Respir Crit Care Med 2000, 162:1783-1788.
24. Bernard G.R., Artigas A., Brigham K.L., et al. The American-European consensus conference on ARDS. Definition, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-824.
25. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874. American College of Chest Physicians/Society of Critical Care Medicine consensus conference.
26. Marshall J.C., Cook D.J., Christou N.V., Bernard G.B., Sprung C.L., Sibbald W.J. Multiple Organ Dysfunction Score. A reliable descriptor of a complex clinical outcome. Crit Care Med 1995, 23:1638-1652.
27. Knaus W.A., Draper E.A., Wanger D., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
28. Sakr Y., Lobo S.M., Moreno R.P., et al. Patterns and early evolution of organ failure in the intensive care unit and their relation to outcome. Crit Care 2012, 16:R222.
29. Muller B., Becker K.L., Schachinger H., et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000, 28:977-983.
30. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
31. Youden W.J. Index for rating diagnostic tests. Cancer 1950, 3:32-35.
32. Wenisch C., Graninger W., Schonthal E., Rumpold H. Increased serum concentrations of the carboxy-terminal cross-linked telopeptide of collagen type I in patients with Gram-negative septicaemia. Eur J Clin Invest 1996, 26:237-239.
33. Nøjgaard C., Johansen J.S., Christensen E., Skovgaard L.T., Price P.A., Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003, 39:179-186.
34. Risteli J., Risteli L. Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J Hepatol 1995, 22:77-81.
35. Bentsen K.D., Boesby S., Kirkegaard P., et al. Is the aminoterminal propeptide of type III procollagen degraded in the liver? A study of type III procollagen peptide in serum during liver transplantation in pigs. J Hepatol 1988, 6:144-150.
36. Keller F., Rehbein C., Schwarz A., et al. Increased procollagen III production in patients with kidney disease. Nephron 1988, 50:332-337.
37. Gaddnas F., Koskela M., Koivukangas V., et al. Skin collagen synthesis is depressed in patients with severe sepsis. Anesth Analg 2010, 111:156-163.
38. Marshall J.C., Reinhart K. Biomarkers of sepsis. Crit Care Med 2009, 37:2290-2298. for the International Sepsis Forum.
39. Dhainaut J.-F., Yan S.B., Joyce D.E., et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with and without overt disseminated intravascular coagulation. J Thromb Haemost 2004, 2:1924-1933.
40. Gerlach H., Dhainaut J.-F., Harbarth S., Reinhart K., Marshall J.C., Levy M. The PIRO concept: R is for response. Crit Care 2003, 7:256-259.